Advertisement

The management of erythrocytosis during testosterone therapy: A practical approach

Published:October 28, 2022DOI:https://doi.org/10.1016/j.ejim.2022.10.018
      Testosterone is the primary sex hormone and anabolic steroid in men. It is a widely used drug which is used by males as an anabolic–androgenic steroid but it is also the cornerstone in treatment of both hypogonadal men and transgender people. This letter will focus on the use of testosterone as therapy for hypogonadal and transgender men. However clinicians may also encounter males who use testosterone as an anabolic–androgenic steroid. In this group we recommend to strongly advice discontinuation of use; and if hematocrit levels exceed >0.55 perform a phlebotomy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Basaria S.
        Male hypogonadism.
        Lancet. 2014; 383 (2014/04/05/): 1250-1263https://doi.org/10.1016/S0140-6736(13)61126-5
        • Ohlander S.J.
        • Varghese B.
        • Pastuszak A.W.
        Erythrocytosis following testosterone therapy.
        Sex Med Rev. 2018; 6: 77-85https://doi.org/10.1016/j.sxmr.2017.04.001
        • Gagnon D.R.
        • Zhang T.J.
        • Brand F.N.
        • Kannel W.B.
        Hematocrit and the risk of cardiovascular disease—the framingham study: a 34-year follow-up.
        Am Heart J. 1994; 127 (1994/03/01/): 674-682https://doi.org/10.1016/0002-8703(94)90679-3
        • Madsen M.C.
        • van Dijk D.
        • Wiepjes C.M.
        • Conemans E.B.
        • Thijs A.
        • den Heijer M.
        Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years.
        J Clin Endocrinol Metab. 2021; 106: 1710-1717https://doi.org/10.1210/clinem/dgab089
        • Jayasena C.N.
        • Anderson R.A.
        • Llahana S.
        • et al.
        Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism.
        Clin Endocrinol. 2022; 96 (Oxf): 200-219https://doi.org/10.1111/cen.14633
        • Hembree W.C.
        • Cohen-Kettenis P.T.
        • Gooren L.
        • et al.
        Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society* clinical practice guideline.
        J Clin Endocrinol Metab. 2017; 102: 3869-3903https://doi.org/10.1210/jc.2017-01658
        • McMullin M.F.F.
        • Mead A.J.
        • Ali S.
        • et al.
        A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis.
        Br J Haematol. 2019; 184: 161-175https://doi.org/10.1111/bjh.15647
        • Keohane C.
        • McMullin M.F.
        • Harrison C.
        The diagnosis and management of erythrocytosis.
        BMJ Br Med J. 2013; 347: f6667https://doi.org/10.1136/bmj.f6667
        • Madsen M.C.
        • van Dijk D.
        • Wiepjes C.M.
        • Conemans E.B.
        • Thijs A.
        • den Heijer M.
        Response to letter to the editor from laidlaw: “erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years.
        J Clin Endocrinol Metab. 2021; 106: e4791-e4792https://doi.org/10.1210/clinem/dgab515
        • Walker R.F.
        • Zakai N.A.
        • MacLehose R.F.
        • et al.
        Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism.
        JAMA Intern Med. 2020; 180: 190-197https://doi.org/10.1001/jamainternmed.2019.5135